Results from the Phase 1 trial of ATH-1105 demonstrated a favorable safety and tolerability profile as well as dose-proportional pharmacokinetics and CNS penetration. ATH-1105 has also demonstrated ...

PepMLM generates binders to challenging therapeutic targets across cancer and neurological disease using protein sequence and ...